Literature DB >> 35353342

NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.

Bin Zhong1, Jie Zheng2, Huilan Wen1, Xinhui Liao1, Xingxiang Chen1, Yunwei Rao1, Ping Yuan3.   

Abstract

BACKGROUND: Non-small cell lung cancer (NSCLC) poses a salient threat to public health. E3 ubiquitin ligase commonly functions as an anti-tumor role.
OBJECTIVE: This study probed the effect of E3 ligase NEDD4L on A549 cells.
METHODS: NEDD4L expression in NSCLC and its correlation with NSCLC patient's prognosis were predicted and verified. PD-L1 protein level was measured, and the correlation between NEDD4L and PD-L1 was analyzed. The effects of NEDD4L overexpression on the binding of NEDD4L to PD-L1 and ubiquitination level of PD-L1 were examined. Xenograft tumor model was established in mice. The volume and weight of xenograft tumors were recorded. The proportion of CD8+ T cells and contents of IL-2 and INF-γ were detected.
RESULTS: NEDD4L expression was downregulated in NSCLC tissues and A549 cells, and correlated with poor prognosis of NSCLC patients. PD-L1 was upregulated in NSCLC and negatively correlated with NEDD4L. Overexpression of NEDD4L upregulated ubiquitination level of PD-L1 and reduced protein level of PD-L1. Overexpression of NEDD4L decreased tumor volume and weight and enhanced proportion of CD8+ T cells and contents of IL-2 and INF-γ.
CONCLUSIONS: Collectively, overexpression of NEDD4L suppressed PD-L1 protein level through ubiquitination, thereby enhancing anti-tumor immune response and retarding NSCLC progression.
© 2022. The Author(s) under exclusive licence to The Genetics Society of Korea.

Entities:  

Keywords:  A549 cells; NEDD4L; Non-small cell lung cancer; PD-L1; Tumor immunity; Ubiquitination

Mesh:

Substances:

Year:  2022        PMID: 35353342     DOI: 10.1007/s13258-022-01238-9

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   2.164


  46 in total

Review 1.  NEDD4-2 (NEDD4L): the ubiquitin ligase for multiple membrane proteins.

Authors:  Pranay Goel; Jantina A Manning; Sharad Kumar
Journal:  Gene       Date:  2014-11-26       Impact factor: 3.688

Review 2.  Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities.

Authors:  Ryan J Davis; Markus Welcker; Bruce E Clurman
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

Review 3.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

Review 4.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review.

Authors:  Bagher Farhood; Masoud Najafi; Keywan Mortezaee
Journal:  J Cell Physiol       Date:  2018-11-22       Impact factor: 6.384

5.  Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient.

Authors:  Chengcheng Gao; Liqun Pang; Chengcheng Ren; Tianheng Ma
Journal:  Med Oncol       Date:  2011-09-11       Impact factor: 3.064

Review 6.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

Authors:  Lieping Chen; Xue Han
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

7.  Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.

Authors:  Sarah E Church; Shawn M Jensen; Paul A Antony; Nicholas P Restifo; Bernard A Fox
Journal:  Eur J Immunol       Date:  2013-11-21       Impact factor: 5.532

Review 8.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

9.  Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.

Authors:  Yan-bin Chen; Chuan-Yong Mu; Jian-An Huang
Journal:  Tumori       Date:  2012-11

10.  Induction and transcriptional regulation of the co-inhibitory gene module in T cells.

Authors:  Norio Chihara; Asaf Madi; Takaaki Kondo; Huiyuan Zhang; Nandini Acharya; Meromit Singer; Jackson Nyman; Nemanja D Marjanovic; Monika S Kowalczyk; Chao Wang; Sema Kurtulus; Travis Law; Yasaman Etminan; James Nevin; Christopher D Buckley; Patrick R Burkett; Jason D Buenrostro; Orit Rozenblatt-Rosen; Ana C Anderson; Aviv Regev; Vijay K Kuchroo
Journal:  Nature       Date:  2018-06-13       Impact factor: 49.962

View more
  1 in total

1.  Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression.

Authors:  Swaroop Kumar Pandey; Anna Shteinfer-Kuzmine; Vered Chalifa-Caspi; Varda Shoshan-Barmatz
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.